Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

Key Inclusion Criteria:

• Male or female subjects aged 18 or older
• Subjects who have a history of AD at least 6 months ago from screening and have beenclinically stable for ≥ 1 month
• Subjects with a clinical diagnosis of AD according to the Hanifin and Rajka Criteriaby a board certified/eligible dermatologist
• Subjects who have a minimum of 5% and a maximum of 30% of total body surface area (BSA) affected by AD at screening and baseline visits
• Subjects with vIGA score 2 or 3 corresponding to mild to moderate AD at screening andbaseline visit
• Subjects should be a literate person who can read the participant information sheetand consent form/questionnaire and understand the language of the participation

Key Exclusion Criteria:

• Subjects who have unstable AD (i.e., remaining clinical stable less than 6 months) orany consistent requirement for any potency topical corticosteroids
• Subjects who have topical treatment with corticosteroids within 2 weeks prior tobaseline visit or other topical treatments of the AD area at screening (moisturizers/emollients are allowed)
• Subjects who had systemic treatment with corticosteroids or cyclosporine or otherimmunosuppressive treatments within 4 weeks prior to baseline visit
• Subjects who had dupilumab or any other biologics within 6 months prior to baselinevisit
• Subjects who take any systemic anti-infective or antibiotic treatments within 1 weekprior to baseline visit
• Subjects who had ultraviolet irradiation (including photopheresis) within 4 weeksprior to screening
• Subjects who have active malignancy or history of cancer in 5 years prior toscreening, except for treated cautions basal cell carcinoma and in situ cervicalcancer
• Subjects who have any other skin diseases that would affect the ability to assess theAD
• Subjects who are taking strong CYP3A4 inhibitor or any other concomitant drug that, inthe opinion of the PI, may cause interference with the treatment
• Subjects who participated in another drug or device trial within 4 weeks prior toscreening...etc